Zynex, Inc. (NASDAQ:ZYXI) just released its latest full-year report and things are not looking great. It wasn't a great result overall - while revenue fell marginally short of analyst estimates at ...

Zynex, Inc. specializes in non-invasive pain management and patient monitoring, with promising advancements like the NiCO pulse oximeter targeting accurate readings for diverse skin tones. Despite ...

Good afternoon, ladies and gentlemen, and welcome to the Zynex fourth-quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. I would now ...

Zynex (NASDAQ:ZYXI) shares plunged in the premarket on Wednesday after the nerve stimulation product maker missed Street forecasts with its Q4 2024 financials, prompting RBC Capital Markets to ...

Ladenburg downgraded Zynex (ZYXI) to Neutral from Buy without a price target saying the company continues to adjust operationally amid revenue pressure. Effectively assess a stock's risks and ...

Royal Bank of Canada cut shares of Zynex (NASDAQ:ZYXI – Free Report) from an outperform rating to a sector perform rating in a research report sent to investors on Wednesday, Marketbeat.com reports.

RBC Capital downgraded Zynex (ZYXI) to Sector Perform from Outperform with a price target of $5.50, down from $11. The firm says the company’s “disappointing update” on its Q4 earnings call ...

Zynex (NASDAQ:ZYXI – Get Free Report) had its price objective lowered by equities researchers at HC Wainwright from $17.00 to $15.00 in a research note issued on Wednesday,Benzinga reports.

Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the Company’s possible violations of ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the ...